Pharmacokinetics & Tolerability Study of MAP0004 in Smoking and Non-Smoking Adult Volunteers
Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
Compare the pharmacokinetics of Dihydroergotamine Mesylate (DHE) delivered by oral inhalation
(MAP0004) or Intravenous (IV) DHE in smokers versus non-smokers.
Identify whether there are clinically significant differences in the tolerability of MAP0004
between smokers and non-smokers.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Allergan
Collaborator:
MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan